License and Collaboration Agreements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Sep. 30, 2021	Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Product revenues, net	$ 188,825	$ 124,926
Settlement charge	0	10,000
Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment for option exercise	187,100
Stock options exercised or expired			0
Development Milestone and Upfront Fee Recognized as Research and Development Expense	100	14,000
Collaborative Arrangement | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent research milestone payments	11,000
Development Milestone and Settlement Upfront Fee Recognized as Research and Development Expense	4,000,000
Collaborative Arrangement | Roche Holding A.G. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Product revenues, net	22,000	22,000
Deferred Revenue	641,500
Deferred Revenue, Current	89,200
Deferred Revenue Separate Material Options Right	485,000			$ 485,000
Research and development expense	17,700	$ 13,400
Collaboration Receivable	$ 17,700